Key clinical point: Quick sequential (sepsis-related) organ failure assessment (qSOFA) is better than the Infectious Disease Society of America/American Thoracic Society minor criteria and worse than confusion, urea, respiratory rate, blood pressure, and age ≥ 65 years (CURB-65) in predicting mortality in community-acquired pneumonia (CAP).

Main finding: The predictive validity of qSOFA for mortality (area under the receiver operating characteristic curve [AUROC] 0.868; 95% CI 0.853-0.882) was higher than that of minor criteria (AUROC 0.824; P < .0001) and lower than that of CURB-65 (AUROC 0.919; P < .0001).

Study details: The data come from an observational prospective cohort study consisting of 2,116 adult patients with CAP.

Disclosures: The study was sponsored by the Medical Science and Technology Foundation of Guangdong Province, Planned Science and Technology Project of Shenzhen Municipality, and Nonprofit Scientific Research Project of Futian District. The authors declared no conflict of interests.

Source: Guo Q et al. Am J Emerg Med. 2022(Feb);52:1-7 (Nov 24). Doi: 10.1016/j.ajem.2021.11.029.

Key clinical point: Quick sequential (sepsis-related) organ failure assessment (qSOFA) is better than the Infectious Disease Society of America/American Thoracic Society minor criteria and worse than confusion, urea, respiratory rate, blood pressure, and age ≥ 65 years (CURB-65) in predicting mortality in community-acquired pneumonia (CAP).

Main finding: The predictive validity of qSOFA for mortality (area under the receiver operating characteristic curve [AUROC] 0.868; 95% CI 0.853-0.882) was higher than that of minor criteria (AUROC 0.824; P < .0001) and lower than that of CURB-65 (AUROC 0.919; P < .0001).

Study details: The data come from an observational prospective cohort study consisting of 2,116 adult patients with CAP.

Disclosures: The study was sponsored by the Medical Science and Technology Foundation of Guangdong Province, Planned Science and Technology Project of Shenzhen Municipality, and Nonprofit Scientific Research Project of Futian District. The authors declared no conflict of interests.

Source: Guo Q et al. Am J Emerg Med. 2022(Feb);52:1-7 (Nov 24). Doi: 10.1016/j.ajem.2021.11.029.

Key clinical point: Quick sequential (sepsis-related) organ failure assessment (qSOFA) is better than the Infectious Disease Society of America/American Thoracic Society minor criteria and worse than confusion, urea, respiratory rate, blood pressure, and age ≥ 65 years (CURB-65) in predicting mortality in community-acquired pneumonia (CAP).

Main finding: The predictive validity of qSOFA for mortality (area under the receiver operating characteristic curve [AUROC] 0.868; 95% CI 0.853-0.882) was higher than that of minor criteria (AUROC 0.824; P < .0001) and lower than that of CURB-65 (AUROC 0.919; P < .0001).

Study details: The data come from an observational prospective cohort study consisting of 2,116 adult patients with CAP.

Disclosures: The study was sponsored by the Medical Science and Technology Foundation of Guangdong Province, Planned Science and Technology Project of Shenzhen Municipality, and Nonprofit Scientific Research Project of Futian District. The authors declared no conflict of interests.

Source: Guo Q et al. Am J Emerg Med. 2022(Feb);52:1-7 (Nov 24). Doi: 10.1016/j.ajem.2021.11.029.

Key clinical point: A positive association exists between blood glucose levels at hospital admission for community-acquired pneumonia (CAP) and 28-day mortality, and the strength of this association decreases with age.

Main finding: After adjusting for confounding factors, all patients exhibited a significant association between blood glucose levels at hospitalization and 28-day mortality (hazard ratio [HR] 2.08; P < .01). After age stratification, this association was evidenced in both middle-aged (HR 4.48; P < .01) and elderly (HR 1.52; P = .05) patients, but was stronger in the former (P = .01).

Study details: This was a retrospective observational study including 1,656 patients aged ≥45 years who were hospitalized for CAP, of which 592 were middle-aged (45-64 years) and 1,064 were elderly (>65 years).

Disclosures: The authors declared no conflict of interests.

Source: Shen Y et al. Int J Gen Med. 2021;14:7775-7781 (Nov 6). Doi: 10.2147/IJGM.S331082.

Key clinical point: A positive association exists between blood glucose levels at hospital admission for community-acquired pneumonia (CAP) and 28-day mortality, and the strength of this association decreases with age.

Main finding: After adjusting for confounding factors, all patients exhibited a significant association between blood glucose levels at hospitalization and 28-day mortality (hazard ratio [HR] 2.08; P < .01). After age stratification, this association was evidenced in both middle-aged (HR 4.48; P < .01) and elderly (HR 1.52; P = .05) patients, but was stronger in the former (P = .01).

Study details: This was a retrospective observational study including 1,656 patients aged ≥45 years who were hospitalized for CAP, of which 592 were middle-aged (45-64 years) and 1,064 were elderly (>65 years).

Disclosures: The authors declared no conflict of interests.

Source: Shen Y et al. Int J Gen Med. 2021;14:7775-7781 (Nov 6). Doi: 10.2147/IJGM.S331082.

Key clinical point: A positive association exists between blood glucose levels at hospital admission for community-acquired pneumonia (CAP) and 28-day mortality, and the strength of this association decreases with age.

Main finding: After adjusting for confounding factors, all patients exhibited a significant association between blood glucose levels at hospitalization and 28-day mortality (hazard ratio [HR] 2.08; P < .01). After age stratification, this association was evidenced in both middle-aged (HR 4.48; P < .01) and elderly (HR 1.52; P = .05) patients, but was stronger in the former (P = .01).

Study details: This was a retrospective observational study including 1,656 patients aged ≥45 years who were hospitalized for CAP, of which 592 were middle-aged (45-64 years) and 1,064 were elderly (>65 years).

Disclosures: The authors declared no conflict of interests.

Source: Shen Y et al. Int J Gen Med. 2021;14:7775-7781 (Nov 6). Doi: 10.2147/IJGM.S331082.

Key clinical point: Lefamulin is suitable as monotherapy against common community-acquired bacterial pneumonia (CABP)-causing pathogens, both typical and atypical, including drug-resistant strains and those causing polymicrobial infections.

Main finding: Lefamulin was as effective as moxifloxacin in the microbiological intent-to-treat (microITT) population, exhibiting a similar early clinical response rate (89.3% vs. 93.0%; difference ‒3.7; 95% CI ‒7.9 to 0.5) and investigator assessment of clinical response success rate (83.2% vs. 86.7%; difference ‒3.3; 95% CI ‒8.6 to 2.0).

Study details: The study analyzed pooled data from the phase 3 noninferiority Lefamulin Evaluation Against Pneumonia 1 and 2 trials, including a total of 1,289 adult patients with CABP (Pneumonia Outcomes Research Team risk classes II-V) who were randomly assigned to receive lefamulin or moxifloxacin. Of these, a baseline CABP pathogen was detected in 709 patients (microITT population).

Disclosures: Nabriva Therapeutics plc (Fort Washington, PA, USA) sponsored the study. Some of the authors, including the lead author, are former or current employees of or stockholders in Nabriva Therapeutics. A few others received research grants/consultation fees from various sources including Nabriva Therapeutics.

Source: Paukner S et al. J Glob Antimicrob Resist. 2021 (Nov 14). Doi: 10.1016/j.jgar.2021.10.021.

Key clinical point: Lefamulin is suitable as monotherapy against common community-acquired bacterial pneumonia (CABP)-causing pathogens, both typical and atypical, including drug-resistant strains and those causing polymicrobial infections.

Main finding: Lefamulin was as effective as moxifloxacin in the microbiological intent-to-treat (microITT) population, exhibiting a similar early clinical response rate (89.3% vs. 93.0%; difference ‒3.7; 95% CI ‒7.9 to 0.5) and investigator assessment of clinical response success rate (83.2% vs. 86.7%; difference ‒3.3; 95% CI ‒8.6 to 2.0).

Study details: The study analyzed pooled data from the phase 3 noninferiority Lefamulin Evaluation Against Pneumonia 1 and 2 trials, including a total of 1,289 adult patients with CABP (Pneumonia Outcomes Research Team risk classes II-V) who were randomly assigned to receive lefamulin or moxifloxacin. Of these, a baseline CABP pathogen was detected in 709 patients (microITT population).

Disclosures: Nabriva Therapeutics plc (Fort Washington, PA, USA) sponsored the study. Some of the authors, including the lead author, are former or current employees of or stockholders in Nabriva Therapeutics. A few others received research grants/consultation fees from various sources including Nabriva Therapeutics.

Source: Paukner S et al. J Glob Antimicrob Resist. 2021 (Nov 14). Doi: 10.1016/j.jgar.2021.10.021.

Key clinical point: Lefamulin is suitable as monotherapy against common community-acquired bacterial pneumonia (CABP)-causing pathogens, both typical and atypical, including drug-resistant strains and those causing polymicrobial infections.

Main finding: Lefamulin was as effective as moxifloxacin in the microbiological intent-to-treat (microITT) population, exhibiting a similar early clinical response rate (89.3% vs. 93.0%; difference ‒3.7; 95% CI ‒7.9 to 0.5) and investigator assessment of clinical response success rate (83.2% vs. 86.7%; difference ‒3.3; 95% CI ‒8.6 to 2.0).

Study details: The study analyzed pooled data from the phase 3 noninferiority Lefamulin Evaluation Against Pneumonia 1 and 2 trials, including a total of 1,289 adult patients with CABP (Pneumonia Outcomes Research Team risk classes II-V) who were randomly assigned to receive lefamulin or moxifloxacin. Of these, a baseline CABP pathogen was detected in 709 patients (microITT population).

Disclosures: Nabriva Therapeutics plc (Fort Washington, PA, USA) sponsored the study. Some of the authors, including the lead author, are former or current employees of or stockholders in Nabriva Therapeutics. A few others received research grants/consultation fees from various sources including Nabriva Therapeutics.

Source: Paukner S et al. J Glob Antimicrob Resist. 2021 (Nov 14). Doi: 10.1016/j.jgar.2021.10.021.

Key clinical point: Reinforcement of antibiotic stewardship by forming large multihospital collaboratives increases adherence to the appropriate 5-day therapy for uncomplicated community-acquired pneumonia (CAP) while decreasing adverse events.

Main finding: After adjusting for hospital clustering, the 20.9% predicted probability of patients receiving a 5-day antibiotic therapy increased to 45.9% (P < .001) over the study period, with the odds of this duration increasing (adjusted odds ratio [aOR] 1.10; 95% CI 1.07-1.14) and composite adverse events decreasing (aOR 0.98; 95% CI 0.96-0.99) with each successive quarter.

Study details: This study included 6,553 patients eligible for a 5-day therapy for uncomplicated CAP who were admitted to any of the 41 hospitals that participated in a state-wide collaborative quality initiative, Michigan Hospital Medicine Safety Consortium, for the entire 3-year study period.

Disclosures: The study was sponsored by Blue Cross Blue Shield of Michigan and a career development award from the Agency for Healthcare Research and Quality to the lead author who, along with other authors, also declared receiving salary, research grants, or speaker honoraria from additional sources.

Source: Vaughn VM et al. Clin Infect Dis. 2021:ciab950 (Nov 13). Doi: 10.1093/cid/ciab950.

Key clinical point: Reinforcement of antibiotic stewardship by forming large multihospital collaboratives increases adherence to the appropriate 5-day therapy for uncomplicated community-acquired pneumonia (CAP) while decreasing adverse events.

Main finding: After adjusting for hospital clustering, the 20.9% predicted probability of patients receiving a 5-day antibiotic therapy increased to 45.9% (P < .001) over the study period, with the odds of this duration increasing (adjusted odds ratio [aOR] 1.10; 95% CI 1.07-1.14) and composite adverse events decreasing (aOR 0.98; 95% CI 0.96-0.99) with each successive quarter.

Study details: This study included 6,553 patients eligible for a 5-day therapy for uncomplicated CAP who were admitted to any of the 41 hospitals that participated in a state-wide collaborative quality initiative, Michigan Hospital Medicine Safety Consortium, for the entire 3-year study period.

Disclosures: The study was sponsored by Blue Cross Blue Shield of Michigan and a career development award from the Agency for Healthcare Research and Quality to the lead author who, along with other authors, also declared receiving salary, research grants, or speaker honoraria from additional sources.

Source: Vaughn VM et al. Clin Infect Dis. 2021:ciab950 (Nov 13). Doi: 10.1093/cid/ciab950.

Key clinical point: Reinforcement of antibiotic stewardship by forming large multihospital collaboratives increases adherence to the appropriate 5-day therapy for uncomplicated community-acquired pneumonia (CAP) while decreasing adverse events.

Main finding: After adjusting for hospital clustering, the 20.9% predicted probability of patients receiving a 5-day antibiotic therapy increased to 45.9% (P < .001) over the study period, with the odds of this duration increasing (adjusted odds ratio [aOR] 1.10; 95% CI 1.07-1.14) and composite adverse events decreasing (aOR 0.98; 95% CI 0.96-0.99) with each successive quarter.

Study details: This study included 6,553 patients eligible for a 5-day therapy for uncomplicated CAP who were admitted to any of the 41 hospitals that participated in a state-wide collaborative quality initiative, Michigan Hospital Medicine Safety Consortium, for the entire 3-year study period.

Disclosures: The study was sponsored by Blue Cross Blue Shield of Michigan and a career development award from the Agency for Healthcare Research and Quality to the lead author who, along with other authors, also declared receiving salary, research grants, or speaker honoraria from additional sources.

Source: Vaughn VM et al. Clin Infect Dis. 2021:ciab950 (Nov 13). Doi: 10.1093/cid/ciab950.

Key clinical point: Patients with severe community-acquired pneumonia (SCAP) who also have type 2 diabetes mellitus (T2DM) have poorer clinical outcomes than those without T2DM.

Main finding: Compared with patients with SCAP but without T2DM, those with both exhibited higher rates of hospital mortality (35.2% vs. 31.0%; P = .009), 14-day mortality (15.0% vs. 10.8%; P < .001), 30-day mortality (25.7% vs. 22.7%; P = .046), and intensive care unit (ICU) mortality (30.8% vs. 26.5%; P = .005) along with a longer ICU length of stay (13 days vs. 12 days; P = .016).

Study details: Findings are from a retrospective, single-center, observational study including 3,786 adult patients admitted to an ICU for SCAP, among whom 1,262 patients with T2DM were matched to 2,524 patients without T2DM.

Disclosures: The study received funding from the National Natural Science Foundation of China, Science and Technology Department of Sichuan Province, and National Key Research and Development Program of China. The authors declared having no conflict of interests.

Source: Huang D et al. Crit Care. 2021;25:419 (Dec 7). Doi: 10.1186/s13054-021-03841-w.

Key clinical point: Patients with severe community-acquired pneumonia (SCAP) who also have type 2 diabetes mellitus (T2DM) have poorer clinical outcomes than those without T2DM.

Main finding: Compared with patients with SCAP but without T2DM, those with both exhibited higher rates of hospital mortality (35.2% vs. 31.0%; P = .009), 14-day mortality (15.0% vs. 10.8%; P < .001), 30-day mortality (25.7% vs. 22.7%; P = .046), and intensive care unit (ICU) mortality (30.8% vs. 26.5%; P = .005) along with a longer ICU length of stay (13 days vs. 12 days; P = .016).

Study details: Findings are from a retrospective, single-center, observational study including 3,786 adult patients admitted to an ICU for SCAP, among whom 1,262 patients with T2DM were matched to 2,524 patients without T2DM.

Disclosures: The study received funding from the National Natural Science Foundation of China, Science and Technology Department of Sichuan Province, and National Key Research and Development Program of China. The authors declared having no conflict of interests.

Source: Huang D et al. Crit Care. 2021;25:419 (Dec 7). Doi: 10.1186/s13054-021-03841-w.

Key clinical point: Patients with severe community-acquired pneumonia (SCAP) who also have type 2 diabetes mellitus (T2DM) have poorer clinical outcomes than those without T2DM.

Main finding: Compared with patients with SCAP but without T2DM, those with both exhibited higher rates of hospital mortality (35.2% vs. 31.0%; P = .009), 14-day mortality (15.0% vs. 10.8%; P < .001), 30-day mortality (25.7% vs. 22.7%; P = .046), and intensive care unit (ICU) mortality (30.8% vs. 26.5%; P = .005) along with a longer ICU length of stay (13 days vs. 12 days; P = .016).

Study details: Findings are from a retrospective, single-center, observational study including 3,786 adult patients admitted to an ICU for SCAP, among whom 1,262 patients with T2DM were matched to 2,524 patients without T2DM.

Disclosures: The study received funding from the National Natural Science Foundation of China, Science and Technology Department of Sichuan Province, and National Key Research and Development Program of China. The authors declared having no conflict of interests.

Source: Huang D et al. Crit Care. 2021;25:419 (Dec 7). Doi: 10.1186/s13054-021-03841-w.

Key clinical point: Owing to a similar clinical efficacy and safety profile to piperacillin-tazobactam (PIP-TAZ), cefoperazone-sulbactam (CFP-SUL) could be used as an alternative for treating severe community-acquired pneumonia (SCAP) in elderly patients.

Main finding: The odds for clinical cure (adjusted odds ratio [aOR] 1.10; 95% CI 0.71-1.70), clinical effectiveness (aOR 0.99; 95% CI 0.62-1.59), all-cause mortality (aOR 0.95; 95% CI 0.60-1.48), and pneumonia-related mortality (aOR 0.88; 95% CI 0.51-1.53) were similar between patients with SCAP receiving CFP-SUL and those receiving PIP-TAZ. Both drug combinations were equally well tolerated.

Study details: Based on the retrospective multicenter registry BATTLE, the study included 624 patients with SCAP among 317 others with hospital- or ventilator-acquired pneumonia who were aged ≥65 years when diagnosed with pneumonia.

Disclosures: The authors disclosed receiving no financial support for the study. None of the authors declared any conflict of interests.

Source: Huang CT et al. Int J Antimicrob Agents. 2021;106491 (Dec 4). Doi: 10.1016/j.ijantimicag.2021.106491.

Key clinical point: Owing to a similar clinical efficacy and safety profile to piperacillin-tazobactam (PIP-TAZ), cefoperazone-sulbactam (CFP-SUL) could be used as an alternative for treating severe community-acquired pneumonia (SCAP) in elderly patients.

Main finding: The odds for clinical cure (adjusted odds ratio [aOR] 1.10; 95% CI 0.71-1.70), clinical effectiveness (aOR 0.99; 95% CI 0.62-1.59), all-cause mortality (aOR 0.95; 95% CI 0.60-1.48), and pneumonia-related mortality (aOR 0.88; 95% CI 0.51-1.53) were similar between patients with SCAP receiving CFP-SUL and those receiving PIP-TAZ. Both drug combinations were equally well tolerated.

Study details: Based on the retrospective multicenter registry BATTLE, the study included 624 patients with SCAP among 317 others with hospital- or ventilator-acquired pneumonia who were aged ≥65 years when diagnosed with pneumonia.

Disclosures: The authors disclosed receiving no financial support for the study. None of the authors declared any conflict of interests.

Source: Huang CT et al. Int J Antimicrob Agents. 2021;106491 (Dec 4). Doi: 10.1016/j.ijantimicag.2021.106491.

Key clinical point: Owing to a similar clinical efficacy and safety profile to piperacillin-tazobactam (PIP-TAZ), cefoperazone-sulbactam (CFP-SUL) could be used as an alternative for treating severe community-acquired pneumonia (SCAP) in elderly patients.

Main finding: The odds for clinical cure (adjusted odds ratio [aOR] 1.10; 95% CI 0.71-1.70), clinical effectiveness (aOR 0.99; 95% CI 0.62-1.59), all-cause mortality (aOR 0.95; 95% CI 0.60-1.48), and pneumonia-related mortality (aOR 0.88; 95% CI 0.51-1.53) were similar between patients with SCAP receiving CFP-SUL and those receiving PIP-TAZ. Both drug combinations were equally well tolerated.

Study details: Based on the retrospective multicenter registry BATTLE, the study included 624 patients with SCAP among 317 others with hospital- or ventilator-acquired pneumonia who were aged ≥65 years when diagnosed with pneumonia.

Disclosures: The authors disclosed receiving no financial support for the study. None of the authors declared any conflict of interests.

Source: Huang CT et al. Int J Antimicrob Agents. 2021;106491 (Dec 4). Doi: 10.1016/j.ijantimicag.2021.106491.

Key clinical point: In patients with chronic obstructive pulmonary disease (COPD), the occurrence of SARS-CoV-2 community-acquired pneumonia (CAP) leads to poorer clinical outcomes than non-SARS-CoV-2 CAP.

Main finding: After adjustment for inverse propensity weighting (IPW) and pneumonia severity index, patients with COPD and SARS-CoV-2 CAP had higher odds of intensive care unit (ICU) admission during hospitalization (IPW-odds ratio [OR] 2.41), invasive mechanical ventilation requirement (IPW-OR 2.23), a cardiovascular event (IPW-OR 4.98), and in-hospital mortality (IPW-OR 7.31) and a longer length of hospital stay (all P < .001) than patients with COPD  who were non-SARS-CoV-2 CAP.

Study details: The analysis compared 96 hospitalized patients with COPD and SARS-CoV-2 CAP with 1,129 patients with COPD and non-SARS-CoV-2 CAP included in the Burden of COVID-19 study and the University of Louisville Pneumonia Study, 2 large observational retrospective and prospective studies, respectively.

Disclosures: The study was sponsored by the Division of Infectious Diseases, University of Louisville. None of the authors reported any conflict of interests.

Source: Sheikh D et al. Respir Med. 2021’191:106714 (Dec 8). Doi: 10.1016/j.rmed.2021.106714.

Key clinical point: In patients with chronic obstructive pulmonary disease (COPD), the occurrence of SARS-CoV-2 community-acquired pneumonia (CAP) leads to poorer clinical outcomes than non-SARS-CoV-2 CAP.

Main finding: After adjustment for inverse propensity weighting (IPW) and pneumonia severity index, patients with COPD and SARS-CoV-2 CAP had higher odds of intensive care unit (ICU) admission during hospitalization (IPW-odds ratio [OR] 2.41), invasive mechanical ventilation requirement (IPW-OR 2.23), a cardiovascular event (IPW-OR 4.98), and in-hospital mortality (IPW-OR 7.31) and a longer length of hospital stay (all P < .001) than patients with COPD  who were non-SARS-CoV-2 CAP.

Study details: The analysis compared 96 hospitalized patients with COPD and SARS-CoV-2 CAP with 1,129 patients with COPD and non-SARS-CoV-2 CAP included in the Burden of COVID-19 study and the University of Louisville Pneumonia Study, 2 large observational retrospective and prospective studies, respectively.

Disclosures: The study was sponsored by the Division of Infectious Diseases, University of Louisville. None of the authors reported any conflict of interests.

Source: Sheikh D et al. Respir Med. 2021’191:106714 (Dec 8). Doi: 10.1016/j.rmed.2021.106714.

Key clinical point: In patients with chronic obstructive pulmonary disease (COPD), the occurrence of SARS-CoV-2 community-acquired pneumonia (CAP) leads to poorer clinical outcomes than non-SARS-CoV-2 CAP.

Main finding: After adjustment for inverse propensity weighting (IPW) and pneumonia severity index, patients with COPD and SARS-CoV-2 CAP had higher odds of intensive care unit (ICU) admission during hospitalization (IPW-odds ratio [OR] 2.41), invasive mechanical ventilation requirement (IPW-OR 2.23), a cardiovascular event (IPW-OR 4.98), and in-hospital mortality (IPW-OR 7.31) and a longer length of hospital stay (all P < .001) than patients with COPD  who were non-SARS-CoV-2 CAP.

Study details: The analysis compared 96 hospitalized patients with COPD and SARS-CoV-2 CAP with 1,129 patients with COPD and non-SARS-CoV-2 CAP included in the Burden of COVID-19 study and the University of Louisville Pneumonia Study, 2 large observational retrospective and prospective studies, respectively.

Disclosures: The study was sponsored by the Division of Infectious Diseases, University of Louisville. None of the authors reported any conflict of interests.

Source: Sheikh D et al. Respir Med. 2021’191:106714 (Dec 8). Doi: 10.1016/j.rmed.2021.106714.

Key clinical point: Combination of dupilumab and topical corticosteroids (TCS) improved signs of atopic dermatitis (AD) rapidly and consistently across all anatomic regions in adults with moderate-to-severe AD.

Major finding: Dupilumab+TCS vs. placebo+TCS significantly improved infiltration/papulation score in head and neck, trunk, and upper extremities; excoriation score in trunk, upper, and lower extremities; lichenification score in trunk by week 2; and erythema score in head and neck and trunk by week 4 (all P ≤ .001), with all improvements sustained until week 52 (P ≤ .001).

Study details: Findings are post hoc analysis of 52-week phase 3 LIBERTY AD CHRONOS trial including 421 patients with moderate-to-severe AD who were randomly assigned to receive dupilumab+TCS or placebo+TCS.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals. Some of the authors declared receiving grants and personal fees or serving as a consultant, speaker, advisory board member, and investigator for various sources. Some of the authors declared being employees or shareholders of Regeneron Pharmaceuticals or Sanofi Genzyme.

Source: Blauvelt A et al. Dermatol Ther (Heidelb). 2021 (Nov 22). Doi: 10.1007/s13555-021-00638-1.

Key clinical point: Combination of dupilumab and topical corticosteroids (TCS) improved signs of atopic dermatitis (AD) rapidly and consistently across all anatomic regions in adults with moderate-to-severe AD.

Major finding: Dupilumab+TCS vs. placebo+TCS significantly improved infiltration/papulation score in head and neck, trunk, and upper extremities; excoriation score in trunk, upper, and lower extremities; lichenification score in trunk by week 2; and erythema score in head and neck and trunk by week 4 (all P ≤ .001), with all improvements sustained until week 52 (P ≤ .001).

Study details: Findings are post hoc analysis of 52-week phase 3 LIBERTY AD CHRONOS trial including 421 patients with moderate-to-severe AD who were randomly assigned to receive dupilumab+TCS or placebo+TCS.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals. Some of the authors declared receiving grants and personal fees or serving as a consultant, speaker, advisory board member, and investigator for various sources. Some of the authors declared being employees or shareholders of Regeneron Pharmaceuticals or Sanofi Genzyme.

Source: Blauvelt A et al. Dermatol Ther (Heidelb). 2021 (Nov 22). Doi: 10.1007/s13555-021-00638-1.

Key clinical point: Combination of dupilumab and topical corticosteroids (TCS) improved signs of atopic dermatitis (AD) rapidly and consistently across all anatomic regions in adults with moderate-to-severe AD.

Major finding: Dupilumab+TCS vs. placebo+TCS significantly improved infiltration/papulation score in head and neck, trunk, and upper extremities; excoriation score in trunk, upper, and lower extremities; lichenification score in trunk by week 2; and erythema score in head and neck and trunk by week 4 (all P ≤ .001), with all improvements sustained until week 52 (P ≤ .001).

Study details: Findings are post hoc analysis of 52-week phase 3 LIBERTY AD CHRONOS trial including 421 patients with moderate-to-severe AD who were randomly assigned to receive dupilumab+TCS or placebo+TCS.

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals. Some of the authors declared receiving grants and personal fees or serving as a consultant, speaker, advisory board member, and investigator for various sources. Some of the authors declared being employees or shareholders of Regeneron Pharmaceuticals or Sanofi Genzyme.

Source: Blauvelt A et al. Dermatol Ther (Heidelb). 2021 (Nov 22). Doi: 10.1007/s13555-021-00638-1.

Key clinical point: Patients with moderate-to-severe atopic dermatitis (AD) are most likely to benefit from long-term 2 mg baricitinib therapy if affected body surface area (BSA) at baseline was 10%-50% and early clinical improvement in itch/skin inflammation was seen after 4-8 weeks of treatment initiation.

Major finding: At week 16, at least 75% improvement in Eczema Area and Severity Index (EASI75) was achieved by a higher proportion of patients treated with 2 mg baricitinib with baseline BSA 10%-50% vs. >50% (37.5% vs. 9.5%) and those with vs. without an early response to 2 mg baricitinib at week 4 (55.4% vs. 16.7%) and week 8 (66.7% vs. 2.1%).

Study details: Findings are post hoc analysis of the ongoing phase 3 BREEZE-AD5 trial including 440 adults with moderate-to-severe AD who were randomly assigned to receive once-daily 1 mg baricitinib, 2 mg baricitinib, or placebo.

Disclosures: This work was funded by Eli Lilly and Company. The authors declared having ties with several sources including Eli Lilly. Four authors declared being current or former employees and shareholders of Eli Lilly.

Source: Silverberg JI et al. Dermatol Ther (Heidelb). 2021 (Nov 30). Doi: 10.1007/s13555-021-00640-7.

Key clinical point: Patients with moderate-to-severe atopic dermatitis (AD) are most likely to benefit from long-term 2 mg baricitinib therapy if affected body surface area (BSA) at baseline was 10%-50% and early clinical improvement in itch/skin inflammation was seen after 4-8 weeks of treatment initiation.

Major finding: At week 16, at least 75% improvement in Eczema Area and Severity Index (EASI75) was achieved by a higher proportion of patients treated with 2 mg baricitinib with baseline BSA 10%-50% vs. >50% (37.5% vs. 9.5%) and those with vs. without an early response to 2 mg baricitinib at week 4 (55.4% vs. 16.7%) and week 8 (66.7% vs. 2.1%).

Study details: Findings are post hoc analysis of the ongoing phase 3 BREEZE-AD5 trial including 440 adults with moderate-to-severe AD who were randomly assigned to receive once-daily 1 mg baricitinib, 2 mg baricitinib, or placebo.

Disclosures: This work was funded by Eli Lilly and Company. The authors declared having ties with several sources including Eli Lilly. Four authors declared being current or former employees and shareholders of Eli Lilly.

Source: Silverberg JI et al. Dermatol Ther (Heidelb). 2021 (Nov 30). Doi: 10.1007/s13555-021-00640-7.

Key clinical point: Patients with moderate-to-severe atopic dermatitis (AD) are most likely to benefit from long-term 2 mg baricitinib therapy if affected body surface area (BSA) at baseline was 10%-50% and early clinical improvement in itch/skin inflammation was seen after 4-8 weeks of treatment initiation.

Major finding: At week 16, at least 75% improvement in Eczema Area and Severity Index (EASI75) was achieved by a higher proportion of patients treated with 2 mg baricitinib with baseline BSA 10%-50% vs. >50% (37.5% vs. 9.5%) and those with vs. without an early response to 2 mg baricitinib at week 4 (55.4% vs. 16.7%) and week 8 (66.7% vs. 2.1%).

Study details: Findings are post hoc analysis of the ongoing phase 3 BREEZE-AD5 trial including 440 adults with moderate-to-severe AD who were randomly assigned to receive once-daily 1 mg baricitinib, 2 mg baricitinib, or placebo.

Disclosures: This work was funded by Eli Lilly and Company. The authors declared having ties with several sources including Eli Lilly. Four authors declared being current or former employees and shareholders of Eli Lilly.

Source: Silverberg JI et al. Dermatol Ther (Heidelb). 2021 (Nov 30). Doi: 10.1007/s13555-021-00640-7.

Key clinical point: Topical tacrolimus (TAC; 0.3% and 0.1%) and topical corticosteroids (TCS) of mild and moderate potency were safe and showed a comparable safety profile in young children with moderate-to-severe atopic dermatitis (AD).

Major finding: Skin-related infections (P = .198), other infections (P = .498), height (P = .601), weight (P = .812), vaccination responses (P = .620), and serum cortisone levels (P = .228) were not significantly different between TAC and TCS groups. In both groups, Eczema Area and Severity Index decreased significantly (P < .0001) and was similar after 36 months (P = .187).

Study details: Findings are from a 36-month follow-up study including 152 children (age 1-3 years) with moderate-to-severe AD who were randomly assigned to receive TCS creams or TAC ointments (0.03% and 0.1%).

Disclosures: The work was supported by the Pediatric Research Foundation, Helsinki University Hospital, Sigrid Juselius Foundation, and others. The authors declared no conflict of interests.

Source: Salava A et al. Clin Exp Dermatol. 2021 (Nov 19). Doi: 10.1111/ced.15024.

Key clinical point: Topical tacrolimus (TAC; 0.3% and 0.1%) and topical corticosteroids (TCS) of mild and moderate potency were safe and showed a comparable safety profile in young children with moderate-to-severe atopic dermatitis (AD).

Major finding: Skin-related infections (P = .198), other infections (P = .498), height (P = .601), weight (P = .812), vaccination responses (P = .620), and serum cortisone levels (P = .228) were not significantly different between TAC and TCS groups. In both groups, Eczema Area and Severity Index decreased significantly (P < .0001) and was similar after 36 months (P = .187).

Study details: Findings are from a 36-month follow-up study including 152 children (age 1-3 years) with moderate-to-severe AD who were randomly assigned to receive TCS creams or TAC ointments (0.03% and 0.1%).

Disclosures: The work was supported by the Pediatric Research Foundation, Helsinki University Hospital, Sigrid Juselius Foundation, and others. The authors declared no conflict of interests.

Source: Salava A et al. Clin Exp Dermatol. 2021 (Nov 19). Doi: 10.1111/ced.15024.

Key clinical point: Topical tacrolimus (TAC; 0.3% and 0.1%) and topical corticosteroids (TCS) of mild and moderate potency were safe and showed a comparable safety profile in young children with moderate-to-severe atopic dermatitis (AD).

Major finding: Skin-related infections (P = .198), other infections (P = .498), height (P = .601), weight (P = .812), vaccination responses (P = .620), and serum cortisone levels (P = .228) were not significantly different between TAC and TCS groups. In both groups, Eczema Area and Severity Index decreased significantly (P < .0001) and was similar after 36 months (P = .187).

Study details: Findings are from a 36-month follow-up study including 152 children (age 1-3 years) with moderate-to-severe AD who were randomly assigned to receive TCS creams or TAC ointments (0.03% and 0.1%).

Disclosures: The work was supported by the Pediatric Research Foundation, Helsinki University Hospital, Sigrid Juselius Foundation, and others. The authors declared no conflict of interests.

Source: Salava A et al. Clin Exp Dermatol. 2021 (Nov 19). Doi: 10.1111/ced.15024.